Nasopharyngeal carcinoma: an evolving paradigm

KCW Wong, EP Hui, KW Lo, WKJ Lam… - Nature reviews Clinical …, 2021 - nature.com
The past three decades have borne witness to many advances in the understanding of the
molecular biology and treatment of nasopharyngeal carcinoma (NPC), an Epstein–Barr virus …

Management of nasopharyngeal carcinoma: current practice and future perspective

AWM Lee, BBY Ma, WT Ng, ATC Chan - Journal of clinical oncology, 2015 - ascopubs.org
Nasopharyngeal carcinoma of the undifferentiated subtype is endemic to southern China,
and patient prognosis has improved significantly over the past three decades because of …

Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

P Bossi, AT Chan, L Licitra, A Trama… - Annals of …, 2021 - annalsofoncology.org
Nasopharyngeal carcinoma (NPC) is a disease with unique epidemiological features. The
distribution of the disease demonstrates a clear regional, racial and gender prevalence. In …

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

SA Rosenberg, JC Yang, RM Sherry, US Kammula… - Clinical cancer …, 2011 - AACR
Purpose: Most treatments for patients with metastatic melanoma have a low rate of complete
regression and thus overall survival in these patients is poor. We investigated the ability of …

Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins

CM Bollard, S Gottschalk, V Torrano, O Diouf… - Journal of Clinical …, 2014 - ascopubs.org
Purpose Tumor cells from approximately 40% of patients with Hodgkin or non-Hodgkin
lymphoma express the type II latency Epstein-Barr virus (EBV) antigens latent membrane …

The role of Epstein–Barr virus in nasopharyngeal carcinoma

ZY Su, PY Siak, CO Leong, SC Cheah - Frontiers in Microbiology, 2023 - frontiersin.org
Nasopharyngeal carcinoma (NPC) is a metastasis-prone malignancy closely associated
with the Epstein–Barr virus (EBV). Despite ubiquitous infection of EBV worldwide, NPC …

Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer

S Mohammed, S Sukumaran, P Bajgain, N Watanabe… - Molecular therapy, 2017 - cell.com
The adoptive transfer of T cells redirected to tumor-associated antigens via transgenic
expression of chimeric antigen receptors (CARs) has produced tumor responses, even in …

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

SA Rosenberg, NP Restifo, JC Yang… - Nature Reviews …, 2008 - nature.com
Adoptive cell therapy (ACT) using autologous tumour-infiltrating lymphocytes has emerged
as the most effective treatment for patients with metastatic melanoma and can mediate …

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

MA Pule, B Savoldo, GD Myers, C Rossig… - Nature medicine, 2008 - nature.com
Cytotoxic T lymphocytes (CTLs) directed to nonviral tumor–associated antigens do not
survive long term and have limited antitumor activity in vivo, in part because such tumor cells …

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

HE Heslop, KS Slobod, MA Pule… - Blood, The Journal …, 2010 - ashpublications.org
T-cell immunotherapy that takes advantage of Epstein-Barr virus (EBV)–stimulated immunity
has the potential to fill an important niche in targeted therapy for EBV-related cancers. To …